Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Actinium Pharmaceuticals and Cytokinetics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Cytokinetics | 1 | 1 | 19 | 0 | 2.86 |
Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 228.95%. Cytokinetics has a consensus price target of $105.44, suggesting a potential upside of 72.21%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Cytokinetics.
Institutional & Insider Ownership
27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Actinium Pharmaceuticals has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.
Profitability
This table compares Actinium Pharmaceuticals and Cytokinetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
| Cytokinetics | -1,321.12% | N/A | -51.01% |
Valuation & Earnings
This table compares Actinium Pharmaceuticals and Cytokinetics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actinium Pharmaceuticals | $35.09 million | 1.36 | -$48.82 million | $0.36 | 4.22 |
| Cytokinetics | $88.04 million | 86.54 | -$784.96 million | ($7.22) | -8.48 |
Actinium Pharmaceuticals has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Actinium Pharmaceuticals beats Cytokinetics on 8 of the 14 factors compared between the two stocks.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
